175Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Belgium
Neuroscience Intelligence
Belgium neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #13 of 50 · Data maturity A · Research score 41.8 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:35 UTC.
41Recruiting trials
174Publications
87Institutions
Executive interpretation
Belgium ranks #13 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Hoffmann-La Roche102 recruiting
University Hospital, Ghent90 recruiting
Merck Sharp & Dohme LLC85 recruiting
Cliniques universitaires Saint-Luc- Université Catholique de Louvain51 recruiting
Universitair Ziekenhuis Brussel52 recruiting
Novartis Pharmaceuticals51 recruiting
Novo Nordisk A/S42 recruiting
UCB Pharma40 recruiting
Bayer43 recruiting
AbbVie41 recruiting
Disease activity
Epilepsy23trials
Alzheimers23trials
Parkinsons18trials
Stroke17trials
Neuromuscular13trials
Other Neurology10trials
Multiple Sclerosis8trials
Pain Neuropathy6trials
Adhd6trials
Migraine Headache4trials
Research institutions
Belgian Society of Medical OncologyOpenAlexlinked institution
International Diabetes FederationOpenAlexlinked institution
VIB-UGent Center for Plant Systems BiologyOpenAlexlinked institution
AZ KlinaOpenAlexlinked institution
European Federation of Allergy and Airways Diseases Patients AssociationsOpenAlexlinked institution
UCLouvain Saint-Louis BrusselsOpenAlexlinked institution
European Organisation for Research and Treatment of CancerOpenAlexlinked institution
Thomas More KempenOpenAlexlinked institution
HOGENT University of Applied Sciences and ArtsOpenAlexlinked institution
Damiaan Dicht bij het levenOpenAlexlinked institution
Clinical evidence trail
NCT07713641Short-Chain Fatty Acids in Lypopolysaccharide-Induced Inflammation and Executive FunctionRECRUITING
NCT07339423AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightRECRUITING
NCT07298044A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to AcoramidisRECRUITING
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT07106632Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic TestsRECRUITING
NCT07033494A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)RECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06744920A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia GravisRECRUITING
NCT06563895Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantRECRUITING
Research evidence trail
PUBMEDDeconfounded, quantitative microbiome profiling identifies robust multiple sclerosis markers and clinical covariate associations.2026-12-31
PUBMEDCurrent practice, clinical perspectives and barriers to multi-night testing for obstructive sleep apnea in Europe: a survey across ESADA centers.2026-12-01
PUBMEDImputation benchmarking in clinical databases: constraint enforcement for bounded neuropsychological assessments.2026-12-01
PUBMEDNovelty seeking and rapid symptom improvement across active and sham accelerated iTBS conditions: A pooled individual-patient data analysis.2026-12-01
PUBMEDAssociation of depression and epilepsy in rural northern Rwanda: a prospective longitudinal study with a patient-centered approach.2026-12-01
PUBMEDEffects of systemic mild hypercapnia on brain function in a refractory cardiac arrest model treated with extracorporeal cardiopulmonary resuscitation.2026-11-01
PUBMEDEBNA1381-452 and Cross-Reactive Antibody Responses Reveal Immune Signatures in Multiple Sclerosis.2026-11-01
PUBMEDPhenotype-driven response to sodium channel blockers in neonatal and infantile genetic epilepsies with tonic seizures.2026-11-01
PUBMEDQuantitative Relationship Between Lumipulse G Measures of pTau217 in Plasma and the Temporal Cortex.2026-10-27
PUBMEDThe neural correlates of walking fatigability in people with multiple sclerosis: An fNIRS study.2026-10-15
PUBMEDEffect of tau silencing on tau pathology propagation, a treatment efficient at the earliest stages of the disease?2026-10-15
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.